Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont
ClinicalTrials.gov Identifier:
NCT00000230
First received: September 20, 1999
Last updated: May 5, 2016
Last verified: August 1996
  Purpose
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.

Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Buprenorphine Detoxification With Two Types of Treatment. BBD III

Resource links provided by NLM:


Further study details as provided by University of Vermont:

Primary Outcome Measures:
  • Drug use
  • Retention
  • Weeks abstinent
  • Weeks continuous abstinence
  • Overall treatment outcome

Estimated Enrollment: 0
Study Start Date: January 1995
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000230

Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

ClinicalTrials.gov Identifier: NCT00000230     History of Changes
Other Study ID Numbers: NIDA-06969-12  R01DA006969  R01-06969-12 
Study First Received: September 20, 1999
Last Updated: May 5, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists

ClinicalTrials.gov processed this record on July 28, 2016